Downregulation of FoxC2 increased susceptibility to experimental colitis: Influence of lymphatic drainage function?

Inflammatory Bowel Diseases

Volumn 21, Issue 6, 2015, Pages 1282-1296

  Becker, Felix ^a,b   Potepalov, Sergey ^a   Shehzahdi, Romana ^a   Bernas, Michael ^c   Witte, Marlys ^c   Abreo, Fleurette ^d   Traylor, James ^d   Orr, Wayne A ^d,e   Tsunoda, Ikuo ^f   Alexander, Jonathan Steven ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d Departments of Verbar Pathology   (United States)

^e Cellular Biology and Anatomy   (United States)

^f LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

DSS colitis; FoxC2; lymphangiogenesis; lymphatic transport failure

Indexed keywords

DEXTRAN SULFATE; TRANSCRIPTION FACTOR FOXC2; FORKHEAD TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DENSITY; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOWN REGULATION; EXPERIMENTAL COLITIS; FEMALE; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHATIC DRAINAGE; MACROPHAGE; MALE; MORPHOLOGY; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; VASCULARIZATION; ANIMAL; CHEMICALLY INDUCED; COLITIS; COLON; DISEASE MODEL; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MORTALITY; NEUTROPHIL CHEMOTAXIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INTESTINAL MUCOSA; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MALE; MICE; NEUTROPHIL INFILTRATION; SURVIVAL RATE;

EID: 84929873409     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000371     Document Type: Article

References (71)

1. Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519-525.
2. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322-337.
3. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.
4. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657.
5. Chidlow JH Jr, Shukla D, Grisham MB, et al. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol. 2007;293:G5-G18.
6. Danese S, Sans M, Spencer DM, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut. 2007;56:855-862.
7. Van Kruiningen HJ, Colombel JF. The forgotten role of lymphangitis in Crohn's disease. Gut. 2008;57:1-4.
8. Alexander JS, Chaitanya GV, Grisham MB, et al. Emerging roles of lymphatics in inflammatory bowel disease. Ann N Y Acad Sci. 2010; 1207(suppl 1):E75-E85.
9. Becker F, Yi P, Al-Kofahi M, et al. Lymphatic dysregulation in intestinal inflammation: new insights into inflammatory bowel disease pathomechanisms. Lymphology. 2014;47:3-27.
10. Alitalo K. The lymphatic vasculature in disease. Nat Med. 2011;17: 1371-1380.
11. Alexander JS, Ganta VC, Jordan PA, et al. Gastrointestinal lymphatics in health and disease. Pathophysiology. 2010;17:315-335.
12. Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol. 2008;3:367-397.
13. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell. 2010;140:460-476.
14. Wijchers PJ, Burbach JP, Smidt MP. In control of biology: of mice, men and foxes. Biochem J. 2006;397:233-246.
15. Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet. 2000;67:1382-1388.
16. Petrova TV, Karpanen T, Norrmen C, et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med. 2004;10:974-981.
17. Kriederman BM, Myloyde TL, Witte MH, et al. FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome. Hum Mol Genet. 2003;12:1179-1185.
18. Dagenais SL, Hartsough RL, Erickson RP, et al. Foxc2 is expressed in developing lymphatic vessels and other tissues associated with lymphedema-distichiasis syndrome. Gene Expr Patterns. 2004;4:611-619.
19. Noon A, Hunter RJ, Witte MH, et al. Comparative lymphatic, ocular, and metabolic phenotypes of Foxc2 haploinsufficient and aP2-FOXC2 transgenic mice. Lymphology. 2006;39:84-94.
20. Norrmen C, Ivanov KI, Cheng J, et al. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol. 2009;185:439-457.
21. Ganta VC, Cromer W, Mills GL, et al. Angiopoietin-2 in experimental colitis. Inflamm Bowel Dis. 2010;16:1029-1039.
22. Jurisic G, Sundberg JP, Detmar M. Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement. Inflamm Bowel Dis. 2013;19:1983-1989.
23. Wu TF, Carati CJ, Macnaughton WK, et al. Contractile activity of lymphatic vessels is altered in the TNBS model of guinea pig ileitis. Am J Physiol Gastrointest Liver Physiol. 2006;291:G566-G574.
24. D'Alessio S, Correale C, Tacconi C, et al. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest. 2014;124:3863-3878.
25. Kim H, Kataru RP, Koh GY. Regulation and implications of inflammatory lymphangiogenesis. Trends Immunol. 2012;33:350-356.
26. Heatley RV, Bolton PM, Hughes LE, et al. Mesenteric lymphatic obstruction in Crohn's disease. Digestion. 1980;20:307-313.
27. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694-702.
28. Vowinkel T, Kalogeris TJ, Mori M, et al. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci. 2004;49:556-564.
29. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114:385-391.
30. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344-1350.
31. Flister MJ, Wilber A, Hall KL, et al. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood. 2010;115:418-429.
32. Chaitanya GV, Omura S, Sato F, et al. Inflammation induces neurolymphatic protein expression in multiple sclerosis brain neurovasculature. J Neuroinflammation. 2013;10:125.
33. Siegmund B, Rieder F, Albrich S, et al. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther. 2001;296: 99-105.
34. Durant L, Watford WT, Ramos HL, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 2010;32:605-615.
35. Soriano A, Salas A, Salas A, et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest. 2000;80:1541-1551.
36. Danese S. Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: "brothers in arms". Gut. 2011;60: 998-1008.
37. Chidlow JH Jr, Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol. 2006;169:2014-2030.
38. Huggenberger R, Siddiqui SS, Brander D, et al. An important role of lymphatic vessel activation in limiting acute inflammation. Blood. 2011; 117:4667-4678.
39. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell. 2002;3:411-423.
40. Shimoda H, Bernas MJ, Witte MH, et al. Abnormal recruitment of periendothelial cells to lymphatic capillaries in digestive organs of angiopoietin-2-deficient mice. Cell Tissue Res. 2007;328:329-337.
41. Lynch PM, Delano FA, Schmid-Schonbein GW. The primary valves in the initial lymphatics during inflammation. Lymphat Res Biol. 2007; 5:3-10.
42. Kitajima S, Takuma S, Morimoto M. Tissue distribution of dextran sulfate sodium (DSS) in the acute phase of murine DSS-induced colitis. J Vet Med Sci. 1999;61:67-70.
43. Morohoshi Y, Matsuoka K, Chinen H, et al. Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodiuminduced colitis. J Gastroenterol. 2006;41:318-324.
44. Taniguchi T, Tsukada H, Nakamura H, et al. Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats. J Gastroenterol Hepatol. 1998;13:945-949.
45. Kane SV, Horst S, Sandborn WJ, et al. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012;18:2203-2208.
46. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13:159-175.
47. Sanz MJ, Kubes P. Neutrophil-active chemokines in in vivo imaging of neutrophil trafficking. Eur J Immunol. 2012;42:278-283.
48. Cueni LN, Detmar M. The lymphatic system in health and disease. Lymphat Res Biol. 2008;6:109-122.
49. Kataru RP, Jung K, Jang C, et al. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood. 2009;113:5650-5659.
50. Angeli V, Randolph GJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res Biol. 2006;4:217-228.
51. Gorlino CV, Ranocchia RP, Harman MF, et al. Neutrophils exhibit differential requirements for homing molecules in their lymphatic and blood trafficking into draining lymph nodes. J Immunol. 2014;193:1966-1974.
52. Teijeira A, Rouzaut A, Melero I. Initial afferent lymphatic vessels controlling outbound leukocyte traffic from skin to lymph nodes. Front Immunol. 2013;4:433.
53. Witte MH, Jones K, Wilting J, et al. Structure function relationships in the lymphatic system and implications for cancer biology. Cancer Metastasis Rev. 2006;25:159-184.
54. Baluk P, Fuxe J, Hashizume H, et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med. 2007;204: 2349-2362.
55. Johnson LA, Clasper S, Holt AP, et al. An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J Exp Med. 2006;203:2763-2777.
56. Bromley SK, Thomas SY, Luster AD. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat Immunol. 2005;6:895-901.
57. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191-1197.
58. Bellingan GJ, Caldwell H, Howie SE, et al. In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J Immunol. 1996;157:2577-2585.
59. Dieleman LA, Ridwan BU, Tennyson GS, et al. Dextran sulfate sodiuminduced colitis occurs in severe combined immunodeficient mice. Gastroenterology. 1994;107:1643-1652.
60. Kim TW, Seo JN, Suh YH, et al. Involvement of lymphocytes in dextran sulfate sodium-induced experimental colitis. World J Gastroenterol. 2006; 12:302-305.
61. Van Kruiningen HJ, Hayes AW, Colombel JF. Granulomas obstruct lymphatics in all layers of the intestine in Crohn's disease. APMIS. 2014;122: 1125-1129.
62. Tabibiazar R, Cheung L, Han J, et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 2006;3:e254.
63. Warren S, Sommers SC. Cicatrizing enteritis as a pathologic entity; analysis of 120 cases. Am J Pathol. 1948;24:475-501.
64. Lockhart-Mummery HE, Morson BC. Crohn's disease of the Large intestine. Gut. 1964;5:493-509.
65. Tonelli P, Martellucci J, Lucchese M, et al. Preliminary results of the influence of the in vivo use of a lymphatic dye (patent blue V) in the surgical treatment of Crohn's disease. Surg Innov. 2013;21:381-388.
66. Kalima TV, Saloniemi H, Rahko T. Experimental regional enteritis in pigs. Scand J Gastroenterol. 1976;11:353-362.
67. Geleff S, Schoppmann SF, Oberhuber G. Increase in podoplaninexpressing intestinal lymphatic vessels in inflammatory bowel disease. Virchows Arch. 2003;442:231-237.
68. Rahier JF, De Beauce S, Dubuquoy L, et al. Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:533-543.
69. Fogt F, Pascha TL, Zhang PJ, et al. Proliferation of D2-40-expressing intestinal lymphatic vessels in the lamina propria in inflammatory bowel disease. Int J Mol Med. 2004;13:211-214.
70. Pedica F, Ligorio C, Tonelli P, et al. Lymphangiogenesis in Crohn's disease: an immunohistochemical study using monoclonal antibody D2-40. Virchows Arch. 2008;452:57-63.
71. Kaiserling E, Krober S, Geleff S. Lymphatic vessels in the colonic mucosa in ulcerative colitis. Lymphology. 2003;36:52-61.